- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.12.25 | Microsize, Schedio link to buy Lonza's Swiss micronization plant | ||
| 01.12.25 | Close of Omnicom-Interpublic megamerger brings new health CEO, 4K layoffs | ||
| 01.12.25 | In UK trade deal, Trump administration excludes drugs from tariffs and secures promise of more pharma investment | ||
| 01.12.25 | Lilly lowers self-pay prices of single-dose Zepbound vials | ||
| 26.11.25 | Medicare unveils price reductions for 15 drugs, including Novo's semaglutide | ||
| 26.11.25 | Novo cashes in FDA national priority voucher for extra-speedy review of high-dose Wegovy | ||
| 26.11.25 | In crowded kidney disease space, Otsuka receives FDA approval for first-in-class Voyxact | ||
| 26.11.25 | French authorities raid Sanofi headquarters in tax fraud probe | ||
| 25.11.25 | Calling all rising stars in pharma marketing: Nominations open for Fierce feature series | ||
| 25.11.25 | Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction | ||
| 25.11.25 | AbbVie short film showcases 'Second Winds' of life after CLL diagnosis | ||
| 25.11.25 | Pharma pros skeptical of letting AI loose on regulatory compliance submissions: survey | ||
| 25.11.25 | Lawmakers probe FDA's new priority voucher program, cite corruption and rushed review concerns | ||
| 25.11.25 | Novartis to cut 550 jobs at plant in Switzerland by end of 2027 | ||
| 25.11.25 | Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M | ||
| 25.11.25 | Angelini faces UK marketing watchdog's wrath after speaker blasts 'stupid' EMA | ||
| 24.11.25 | SK Life Science Xcopri ad meets a roadblock with FDA untitled letter | ||
| 24.11.25 | Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease | ||
| 24.11.25 | Merck's partner Kelun touts phase 3 win for ADC-Keytruda combo in first-line lung cancer | ||
| 21.11.25 | AstraZeneca boosts its presence in Maryland with $2B manufacturing investment | ||
| 21.11.25 | FDA grants game-changing perioperative approval to Padcev, Keytruda combo in bladder cancer | ||
| 21.11.25 | FDA launches investigation into Takeda's Adzynma following reported pediatric death | ||
| 21.11.25 | Australian government rejects Cosette's proposed Mayne Pharma buyout, citing 'national interest' | ||
| 21.11.25 | Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing | ||
| 21.11.25 | GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .